Brief: Biomea Fusion Reports First Quarter 2023 Financial Results And Corporate Highlights
02/05/2023 22:38
May 2 (Reuters) - Biomea Fusion Inc BMEA.O :
* BIOMEA FUSION REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS
AND
CORPORATE HIGHLIGHTS
* BIOMEA FUSION INC - IN 2023, WE EXPECT TO CONTINUE TO
ADVANCE
OUR CLINICAL PROGRAMS IN DIABETES AND ONCOLOGY
* BIOMEA FUSION INC - AS OF MARCH 31, 2023, COMPANY HAD
CASH, CASH
EQUIVALENTS, RESTRICTED CASH, AND INVESTMENTS OF $86.7 MILLION
* BIOMEA FUSION INC - QTRLY LOSS PER SHARE $0.98
Source text for Eikon: ID:nGNX27zNMt
Further company coverage: BMEA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Biomea Fusion
See all newsUS RESEARCH ROUNDUP-BlackRock, Microsoft, TransDigm Group
Brief: Biomea Fusion Announces Phase 1 Results For Bmf-650, Its Investigational Next-Generation Oral Small Molecule Glp-1 Receptor Agonist
Brief: Biomea Fusion To Announce Phase I Results For Bmf-650, Its Next-Generation Oral Small-Molecule Glp-1 Receptor Agonist
Brief: Biomea Fusion Announces Termination Of Proposed Public Offering Of Securities
Brief: Biomea Fusion Announces Completion Of Enrollment In Covalent-211 Phase Ii Trial Of Icovamenib In Insulin-Deficient Type 2 Diabetes